Progress made towards the development of a CMV peptide vaccine

Human Immunology

Volumn 65, Issue 5, 2004, Pages 544-549

  Paston, S J ^a   Dodi, I A ^a   Madrigal, J A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

CMV; epitopes; hematopoietic stem cell transplantation; IE1; pp65

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN GB; CYTOMEGALOVIRUS ANTIGEN IE1; CYTOMEGALOVIRUS ANTIGEN PP150; CYTOMEGALOVIRUS ANTIGEN PP28; CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; EPITOPE; HLA ANTIGEN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ALLELE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMORAL IMMUNITY; LATENT PERIOD; MAJOR HISTOCOMPATIBILITY COMPLEX; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RECIPIENT; REVIEW;

EID: 2542503295     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2004.02.005     Document Type: Article

References (43)

1. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis. 12:(Suppl 7):1990;S701
2. Meyers J.D., Flournoy N., Thomas E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 153:1986;478
3. Sinclair J., Sissons P. Latent and persistent infections of monocytes and macrophages. Intervirology. 39:1996;293
4. Cwynarski K., Ainsworth J., Cobbold M., Wagner S., Mahendra P., Apperley J., Goldman J., Craddock C., Moss P.A. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood. 97:2001;1232
5. Aubert G., Hassan-Walker A.F., Madrigal J.A., Emery V.C., Morte C., Grace S., Koh M.B., Potter M., Prentice H.G., Dodi I.A., Travers P.J. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis. 184:2001;955
6. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., Sissons J.G. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65 frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol. 70:1996;7569
7. Riddell S.R., Rabin M., Geballe A.P., Britt W.J., Greenberg P.D. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol. 146:1991;2795
8. Britt W.J., Vugler L., Butfiloski E.J., Stephens E.B. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB) use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol. 64:1990;1079
9. Gonczol E., deTaisne C., Hirka G., Berencsi K., Lin W.C., Paoletti E., Plotkin S. High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant the importance of the gB protein in HCMV immunity. Vaccine. 9:1991;631
10. Riddell S.R., Reusser P., Greenberg P.D. Cytotoxic T cells specific for cytomegalovirus a potential therapy for immunocompromised patients. Rev Infect Dis. 13:(Suppl 11):1991;S966
11. Marshall G.S., Stout G.G., Knights M.E., Rabalais G.P., Ashley R., Miller H., Rossier E. Ontogeny of glycoprotein gB-specific antibody and neutralizing activity during natural cytomegalovirus infection. J Med Virol. 43:1994;77
12. Gyulai Z., Endresz V., Burian K., Pincus S., Toldy J., Cox W.I., Meric C., Plotkin S., Gonczol E., Berencsi K. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals reevaluation of prevalence of IE1-specific CTLs. J Infect Dis. 181:2000;1537
13. Kern F., Surel I.P., Faulhaber N., Frommel C., Schneider-Mergener J., Schonemann C., Reinke P., Volk H.D. Target structures of the CD8(+)-T-cell response to human cytomegalovirus the 72-kilodalton major immediate-early protein revisited. J Virol. 73:1999;8179
14. Diamond D.J., York J., Sun J.Y., Wright C.L., Forman S.J. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood. 90:1997;1751
15. Solache A., Morgan C.L., Dodi A.I., Morte C., Scott I., Baboonian C., Zal B., Goldman J., Grundy J.E., Madrigal J.A. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J Immunol. 163:1999;5512
16. Gallot G., Vivien R., Ibisch C., Lule J., Davrinche C., Gaschet J., Vie H. Purification of Ag-specific T lymphocytes after direct peripheral blood mononuclear cell stimulation followed by CD25 selection. I. Application to CD4(+) or CD8(+) cytomegalovirus phosphoprotein pp65 epitope determination. J Immunol. 167:2001;4196
17. Kern F., Surel I.P., Brock C., Freistedt B., Radtke H., Scheffold A., Blasczyk R., Reinke P., Schneider-Mergener J., Radbruch A., Walden P., Volk H.D. T-cell epitope mapping by flow cytometry. Nat Med. 4:1998;975
18. Kern F., Khatamzas E., Surel I., Frommel C., Reinke P., Waldrop S.L., Picker L.J., Volk H.D. Distribution of human CMV-specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms. Eur J Immunol. 29:1999;2908
19. Dunn H.S., Haney D.J., Ghanekar S.A., Stepick-Biek P., Lewis D.B., Maecker H.T. Dynamics of CD4 and CD8 T cell responses to cytomegalovirus in healthy human donors. J Infect Dis. 186:2002;15
20. Kern F., Bunde T., Faulhaber N., Kiecker F., Khatamzas E., Rudawski I.M., Pruss A., Gratama J.W., Volkmer-Engert R., Ewert R., Reinke P., Volk H.D., Picker L.J. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis. 185:2002;1709
21. Smith K.D., Lutz C.T. Peptide-dependent expression of HLA-B7 on antigen processing-deficient T2 cells. J Immunol. 156:1996;3755
22. Takiguchi M., Kawaguchi G., Sekimata M., Hiraiwa M., Kariyone A., Takamiya Y. The role of the conserved residue in pocket A and the polymorphic residue in pocket E of HLA-B*3501 in presentation of human minor histocompatibility peptides to T cells. Int Immunol. 6:1994;1345
23. Zweerink H.J., Gammon M.C., Utz U., Sauma S.Y., Harrer T., Hawkins J.C., Johnson R.P., Sirotina A., Hermes J.D., Walker B.D., et al. Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J Immunol. 150:1993;1763
24. Elkington R., Walker S., Crough T., Menzies M., Tellam J., Bharadwaj M., Khanna R. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol. 77:2003;5226
25. Gallez-Hawkins G., Villacres M.C., Li X., Sanborn M.C., Lomeli N.A., Zaia J.A. Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response. J Virol. 77:2003;4457
26. Frankenberg N., Pepperl-Klindworth S., Meyer R.G., Plachter B. Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus. Virology. 295:2002;208
27. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stevanovic S. SYFPEITHI database for MHC ligands and peptide motifs. Immunogenetics. 50:1999;213
28. Parker K.C., Bednarek M.A., Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 152:1994;163
29. Sette A., Vitiello A., Reherman B., Fowler P., Nayersina R., Kast W.M., Melief C.J., Oseroff C., Yuan L., Ruppert J., et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol. 153:1994;5586
30. Longmate J., York J., La Rosa C., Krishnan R., Zhang M., Senitzer D., Diamond D.J. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics. 52:2001;165
31. Lacey S.F., Villacres M.C., La Rosa C., Wang Z., Longmate J., Martinez J., Brewer J.C., Mekhoubad S., Maas R., Leedom J.M., Forman S.J., Zaia J.A., Diamond D.J. Relative dominance of HLA-B*07 restricted CD8(+) T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol. 64:2003;440
32. Gilbert M.J., Riddell S.R., Plachter B., Greenberg P.D. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature. 383:1996;720
33. Kern F., Faulhaber N., Frommel C., Khatamzas E., Prosch S., Schonemann C., Kretzschmar I., Volkmer-Engert R., Volk H.D., Reinke P. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol. 30:2000;1676
34. Khan N., Shariff N., Cobbold M., Bruton R., Ainsworth J.A., Sinclair A.J., Nayak L., Moss P.A. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol. 169:2002;1984
35. Cook C.H., Yenchar J.K., Kraner T.O., Davies E.A., Ferguson R.M. Occult herpes family viruses may increase mortality in critically ill surgical patients. Am J Surg. 176:1998;357
36. Cook C.H., Zhang Y., McGuinness B.J., Lahm M.C., Sedmak D.D., Ferguson R.M. Intra-abdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice. J Infect Dis. 185:2002;1395
37. Hummel M., Zhang Z., Yan S., DePlaen I., Golia P., Varghese T., Thomas G., Abecassis M.I. Allogeneic transplantation induces expression of cytomegalovirus immediate-early genes in vivo a model for reactivation from latency. J Virol. 75:2001;4814
38. Hebart H., Daginik S., Stevanovic S., Grigoleit U., Dobler A., Baur M., Rauser G., Sinzger C., Jahn G., Loeffler J., Kanz L., Rammensee H.G., Einsele H. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood. 99:2002;3830
39. Masuoka M., Yoshimuta T., Hamada M., Okamoto M., Fumimori T., Honda J., Oizumi K., Itoh K. Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes. Viral Immunol. 14:2001;369
40. Kuzushima K., Hayashi N., Kimura H., Tsurumi T. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood. 98:2001;1872
41. Gavin M.A., Gilbert M.J., Riddell S.R., Greenberg P.D., Bevan M.J. Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. J Immunol. 151:1993;3971
42. Wills M.R., Okecha G., Weekes M.P., Gandhi M.K., Sissons P.J., Carmichael A.J. Identification of naive or antigen-experienced human CD8(+) T cells by expression of costimulation and chemokine receptors analysis of the human cytomegalovirus-specific CD8(+) T cell response. J Immunol. 168:2002;5455
43. Retiere C., Prod'homme V., Imbert-Marcille B.M., Bonneville M., Vie H., Hallet M.M. Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins a tool to study the fine specificity of the antiviral response. J Virol. 74:2000;3948